These findings reveal a novel PABPC1-PGK1 regulatory axis underlying sunitinib resistance and suggest a promising therapeutic strategy for overcoming drug resistance in ccRCC. This evidence concerns the gene PABPC1 and nonpapillary renal cell carcinoma.